MedTrace Logo

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-14

No results posted yet for this study

Summary

The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Conditions

  • Lipoprotein Disorder

Interventions

DRUG

DII235

Solution for injection

DRUG

Saline

solution for injection

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2027-09-08
Completion
2028-09-08
FDA Drug
Yes

Countries

  • United States
  • China
  • Germany
  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07235046 on ClinicalTrials.gov